Eyebiotech Ltd.
Clinical trials sponsored by Eyebiotech Ltd., explained in plain language.
-
New eye drug EYE103 aims to restore vision in macular degeneration and vein occlusion
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called EYE103 (Restoret) in 160 people with wet age-related macular degeneration or macular edema from a branch retinal vein occlusion. Participants receive three eye injections of either a low or high dose of EYE103, spaced four week…
Phase: PHASE2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
New eye drug tiespectus takes on aflibercept in major wet AMD trial
Disease control Recruiting nowThis study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New eye drug could rival standard treatment for blinding disease
Disease control Recruiting nowThis study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus works as…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC